Robert W. Baird & Co. has announced that David Schechner has joined the firm’s Healthcare Investment Banking team as a new Managing Director. Mr. Schechner has more than 20 years of investment banking experience in the biotechnology and pharmaceutical space. He will be active in Baird’s life sciences banking practice and will be based in Boston.
Mr. Schechner joins Baird from Canaccord Genuity where he led their biotechnology and pharmaceutical banking group since 2008. Prior to Canaccord, he founded and led the biotechnology banking group at Needham & Company for seven years. Mr. Schechner has also held senior investment banking roles at Goldman Sachs and Bear Stearns, focusing on healthcare and telecommunications. Mr. Schechner has an MBA from the Harvard Graduate School of Business and graduated with a degree in economics from Cornell University.
The addition of Mr. Schechner follows other recent addition by Baird to its investment banking team including Chris Harned in Milwaukee, Paul Bail in London, Jason Abt and Owen Hart in San Francisco and Rob Rosenfeld in Chicago. Baird’s investment banking group posted record revenues in 2011, 42% higher than its previous record set in 2007.
